Figure 3
From: Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma
Kaplan–Meier survival curves for overall survival time from the progression of first-line chemotherapy between the patients who received second-line chemotherapy and those who did not. Survival curve of the patients who did not receive (No 2nd chemotherapy) (continuous line) and those who received second-line chemotherapy (2nd-line) (dotted line) are shown (a). Survival curve of the patients who did not receive second-line chemotherapy owing to patient refusal (Reject) (continuous line) and those received second-line chemotherapy (2nd-line) (dotted line line) are shown (b).
